Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis

Molecular Therapy

Volumn 9, Issue 1, 2004, Pages 30-37

  Miranda Díaz, Alejandra ^a   Rincón, Ana Rosa ^a   Salgado, Silvia ^a   Vera Cruz, José ^a   Gálvez, Javier ^a   Islas, Ma Cristina ^a   Berumen, Jaime ^b   Aguilar Cordova, Estuardo ^c   Armendáriz Borunda, Juan ^a,d  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b HOSPITAL GENERAL DE MÉXICO   (Mexico)

^c Advantagene Inc   (United States)

^d HOSPITAL CIVIL DE GUADALAJARA FRAY ANTONIO ALCALDE   (Mexico)

Author keywords

Bile duct injury; Coadjuvant gene therapy; Fibrosis reversion

Indexed keywords

ADENOVIRUS VECTOR; BILIRUBIN; GELATINASE A; GELATINASE B; GREEN FLUORESCENT PROTEIN; STROMELYSIN; UROKINASE; UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; BILE DUCT BYPASS; BILIARY CIRRHOSIS; CHOLESTASIS; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; LIVER REGENERATION; NONHUMAN; PROTEIN EXPRESSION; RAT; STOMACH VARICES; TREATMENT OUTCOME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ADENOVIRIDAE; ANIMALIA;

EID: 1142275284     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.09.015     Document Type: Article

References (29)

1. Starzl, T. E., Demetris, A. J., and Van Thiel, D. (1989). Liver transplantation (1). N. Engl. J. Med. 321: 1014-1022.
2. Whitington, P. F., and Balistreri, W. F. (1991). Liver transplantation in pediatrics: Indications, contraindications, and pretransplant management. J. Pediatr. 118: 169-177.
3. Poupon, R., Chazouilleres, O., and Poupon, R. E. (2000). Chronic cholestatic diseases. J. Hepatol. 32(Suppl. 1): 129-140.
4. Friedman, S. L. (1993). The cellular basis of hepatic fibrosis: Mechanisms and treatment strategies. N. Engl. J. Med. 328: 1828-1835.
5. Rossi, R. L., and Tsao, J. L. (1994). Biliary reconstruction. Surg. Clin. North Am. 74: 825-844.
6. Poupon, R. E., Balkau, B., Eschwege, E., and Poupon, R. (1991). A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N. Engl. J. Med. 324: 1548-1554.
7. Kaplan, M. M., DeLellis, R. A., and Wolfe, H. J. (1997). Sustained biochemical and histologic remission of primary biliary cirrhosis in response to medical treatment. Ann. Intern. Med. 126: 682-688.
8. Zimmerman, H., Reichen, J., Zimmermann, A., Sagesser, H., Thenisch, B., and Hoflin, F. (1992). Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Gastroenterology 103: 579-589.
9. Zhong, Z., Froh, M., Wheeler, M. D., Smutney, O., Lehmann, T. G., and Thurman, R. G. (2002). Viral gene delivery of superoxide dismutase attenuates experimental cholestasis-induced liver fibrosis in the rat. Gene Ther. 9: 183-191.
10. Salgado, S., et al. (2000). Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Mol. Ther. 2: 545-551.
11. Lieber, A., Peeters, M. J., Gown, A., Perkins, J., and Kay, M. A. (1995). A modified urokinase plasminogen activator induces liver regeneration without bleeding. Hum. Gene Ther. 6: 1029-1037.
12. Nyberg-Hoffman, C., Shabram, P., Li, W., Giroux, D., and Aguilar-Cordova, E. (1997). Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3: 808-811.
13. García-Bañuelos, J., Siller-Löpez, F., Miranda, A., Aguilar, L. K., Aguilar-Córdova, E., and Armendáriz-Borunda, J. (2002). Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors: Evidence of cirrhosis reversion. Gene Ther. 9: 127-134.
14. Lopez-De Leon, A., and Rojkind, M. (1985). A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded section. J. Histochem. Cytochem. 33: 737-743.
15. Bueno, M. R., Daneri, A., and Armendáriz-Borunda, J. (2000). Cholestasis-induced fibrosis is reduced by interferon alpha-2a and is associated with elevated liver metalloprotease activity. J. Hepatol. 33: 915-925.
16. Sukin, S. W., et al. (2001). In vivo surgical resection plus adjuvant gene therapy in the treatment of mammary and prostate cancer. Mol. Ther. 3: 500-506.
17. Chhikara, M., et al. (2001). Enhanced therapeutic effect of HSV-tk + GCV gene therapy and ionizing radiation for prostate cancer. Mol. Ther. 3: 536-542.
18. Kasai, M. (1974). Treatment of biliary atresia with special reference to hepatic portoenterostomy and its modifications. Prog. Pediatr. Surg. 6: 5-52.
19. Karrer, F. M., et al. (1996). Long-term results with the Kasai operation for biliary atresia. Arch. Surg. 131: 493-496.
20. Stiehl, A., et al. (1990). Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 12: 492-497.
21. Skulina, D., et al. (1999). The influence of ursodeoxycholic acid on some biochemical, immunologic and histopathologic parameters in patients with primary biliary cirrhosis. Przegl Lek. 56: 201-204.
22. Murr, M., Gigot, J. F., Nagorney, D. M., Harmsen, W. S., Ilstrup, D. M., and Farnell, M. B. (1999). Long-term results of biliary reconstruction after laparoscopic bile duct injuries. Arch. Surg. 134: 604-610.
23. Pickleman, J., Marsan, R., and Borge, M. (2000). Portoenterostomy: An old treatment for a new disease. Arch. Surg. 135: 811-817.
24. Dickson, E. R., Grambsch, P. M., Fleming, T. R., Fisher, L. D., and Langoworthy, A. (1989). Prognosis in primary biliary cirrhosis: Model for decision making. Hepatology 10: 1-7.
25. Miga, D., Sokol, R. J., Mackenzie, T., Narkewicz, M. R., Smith, D., and Karrer, F. M. (2001). Survival after first esophageal variceal hemorrhage in patients with biliary atresia. J. Pediatr. 139: 291-296.
26. Bonnand, A. M., Heathcote, E. J., Lindor, K. D., and Poupon, R. E. (1999). Clinical significance of serum bilirubin levels under ursodeoxycholic acid therapy in patients with primary biliary cirrhosis. Hepatology 29: 39-43.
27. Shapiro, J. M., Smith, H., and Schaffner, F. (1979). Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 20: 137-140.
28. 4-induced in liver fibrosis, persistence of activated hepatic stellate cells, and diminished hepatocyte regeneration. FASEB J. 17: 47-49.
29. Iimuro, Y., et al. (2003). Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 124: 445-458.